B.Riley Financial analyst Neil Chatterji reiterated a Buy rating on Augmedix (AUGX – Research Report) today and set a price target of $6.50. The company’s shares closed yesterday at $4.07.
According to TipRanks, Chatterji is a 3-star analyst with an average return of 4.0% and a 35.09% success rate. Chatterji covers the Healthcare sector, focusing on stocks such as Silk Road Medical, Stereotaxis, and OptimizeRx.
Currently, the analyst consensus on Augmedix is a Strong Buy with an average price target of $6.83.
See Insiders’ Hot Stocks on TipRanks >>
AUGX market cap is currently $164.8M and has a P/E ratio of -6.41.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AUGX in relation to earlier this year. Most recently, in May 2023, Traylor Margie L., a Director at AUGX bought 10,182.00 shares for a total of $22,400.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Augmedix Inc humanizes the clinician-patient experience by enabling clinicians to focus on what matters most, delivering high-quality patient care. It converts natural clinician-patient conversation into medical documentation and provides real-time administrative support, including referrals, orders, and reminders. The service, which supports over 35 specialties, delivers timely, accurate and comprehensive medical documentation to several of the healthcare systems in the U.S. and to hundreds of independent clinicians nationwide. Augmedix focuses on saving clinicians 2-3 hours per day, improve clinician productivity by as much as 20%, and increase clinicians’ satisfaction with work-life balance over 40%.
Read More on AUGX:
- Augmedix Delivers 47% Revenue Growth and Expanded Gross Margins for Second Quarter of 2023
- AUGX Earnings this Week: How Will it Perform?
- Augmedix to Announce Second Quarter 2023 Financial Results and Host Investor Conference Call on August 7, 2023
- Augmedix extends term loan facility, finalizes terms for line of credit
- Augmedix Extends Term Loan Facility and Finalizes Terms for Equity Line of Credit
